Making Strides in Protein Characterization

February 1, 2011

The bioprocessing industry continues to transform and reinvent itself as a range of new technologies is introduced and adopted. The sequencing of the human genome has made available a wealth of targets for drug development, translating into a demand for appropriate biotherapeutics. Moreover, the expiration of patent protection for many biologics is fueling increasing interest in biosimilars.

Read the full article

About Us

Newport Biotechnology Consultants, founded in 2005, originally was aimed at providing writing expertise in the life sciences industry, with a specialization in molecular immunology. I drew upon my academic and industrial background to cover new developments and technologies in antibody therapies and related areas of biotechnology. These reviews were published in a number of trade journals, especially articles in Genetic Engineering and Biotechnology News (see articles). More recently I have expanded my writing into other fields, including emergency management, drug discovery, bioprocessing, environmental and sustainable technologies, micro- and nanotechnology and many other areas. I also am involved in regulatory issues. I am Chair of the Meridian Bioscience Institutional Biosafety Committee, and I am a member of the Cincinnati Children’s Medical Center Institutional Biosafety Committee (see consulting services). Both IBCs review research protocols dealing with the use of recombinant DNA. Finally, I have consulted for a number of companies on laboratory design, business plan evaluation and regulatory questions.

Videos, Slideshows and Podcasts by Cincopa Wordpress Plugin